ARTICLE | Clinical News
Antegren natalizumab: Phase II
January 29, 2001 8:00 AM UTC
In a 213-patient double-blind Phase II study in the U.S., Canada and U.K., the companies said that monthly injections of Antegren gave a significant reduction in new gadolinium-enhancing lesions after...